ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mavacamten

Also written as “Mavacamten” and “MYK-461”.

Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.

Drug pageMYK-461: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 27, 202321 company-led studies, 4 open or runningNext primary completion: Dec 13, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only194 open or runningphase 4since Oct 27, 2023Dec 19, 2014Dec 13, 2027phase 4 · NCT07004972
LianBioits history only20 open or runningphase 3since Dec 13, 2021Oct 28, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 7 earlier studies, Dec 19, 2014 to Apr 5, 2018.

  1. Dec 9, 2016Named mavacamtenINNProposed as its International Nonproprietary Name in WHO's List 116 · before, MYK-461
  2. Oct 24, 2018Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT03723655 · 314 enrolled · United States, Belgium, Czechia and more
  3. Apr 7, 2020Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT04349072 · 112 enrolled · United States
  4. Feb 16, 2021Phase 2 study in Cardiomyopathy, Familial Restrictive, 3Bristol-Myers Squibb · NCT04766892 · 30 enrolled · United States, Canada
  5. Oct 28, 2021LianBio’s first study: phase 1 study in Cardiomyopathy, HypertrophicNew to LianBioLianBio · NCT05135871 · 45 enrolled · China
  6. Dec 13, 2021Phase 3 study in Cardiomyopathy, HypertrophicLianBio · NCT05174416 · 81 enrolled · China
  7. Apr 1, 2022Phase 1 study in AnthraxBristol-Myers Squibb · NCT05320094 · 45 enrolled · United States
  8. May 2, 2022Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05362045 · 158 enrolled · United States
  9. Jun 7, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05414175 · 38 enrolled · Japan
  10. Sep 14, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05582395 · 580 enrolled · United States, Australia, Austria and more
  11. Jan 31, 2023Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05719805 · 84 enrolled · United States
  12. Oct 27, 2023Phase 4 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06112743 · 63 enrolled · United States, Argentina, Australia and more
  13. Feb 2, 2024Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06253221 · 44 enrolled · United States, Australia, Canada and more
  14. May 26, 2025Phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972 · 50 enrolled · India
  15. Oct 29, 2026Phase 3 study in CardiomyopathiesBristol-Myers Squibb · NCT07940777 · 500 planned

Ahead

  1. Dec 13, 2027Primary completion: phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972
  2. Jul 21, 2029Primary completion: phase 3 study in CardiomyopathiesBristol-Myers Squibb · NCT07940777

TargetBeta

“Cardiac myosin inhibitor”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
omecamtiv mecarbilruleCytokineticsphase 316
danicamtivruleBristol-Myers Squibbphase 37

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07940777Cardiomyopathies3Not yet recruitingBristol-Myers SquibbJul 21, 2029500
NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy · India4Active, not recruitingBristol-Myers SquibbDec 13, 202750
NCT06253221Cardiomyopathy, Hypertrophic · United States, Australia, Canada and more3Active, not recruitingBristol-Myers SquibbNov 25, 202544
NCT06112743Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more4Active, not recruitingBristol-Myers SquibbJul 16, 202663
NCT05719805Cardiomyopathy, Hypertrophic · United States1CompletedBristol-Myers SquibbJul 25, 202384
NCT05582395Cardiomyopathy, Hypertrophic · United States, Australia, Austria and more3TerminatedBristol-Myers SquibbMar 6, 2025580
NCT05414175Cardiomyopathy, Hypertrophic · Japan3CompletedBristol-Myers SquibbNov 27, 202338
NCT05362045Cardiomyopathy, Hypertrophic · United States1CompletedBristol-Myers SquibbAug 19, 2022158
NCT05320094Anthrax · United States1CompletedBristol-Myers SquibbSep 11, 202245
NCT05174416Cardiomyopathy, Hypertrophic · China3CompletedLianBioMar 6, 202381
NCT05135871Cardiomyopathy, Hypertrophic · China1CompletedLianBioFeb 5, 202245
NCT04766892Cardiomyopathy, Familial Restrictive, 3 · United States, Canada2CompletedBristol-Myers SquibbFeb 26, 202430
NCT04349072Cardiomyopathy, Hypertrophic · United States3CompletedBristol-Myers SquibbFeb 7, 2022112
NCT03723655Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more3CompletedBristol-Myers SquibbJan 16, 2026314
NCT03496168Cardiomyopathy, Hypertrophic · United States2CompletedBristol-Myers SquibbNov 9, 202313
NCT03470545Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more3CompletedBristol-Myers SquibbMar 14, 2020251
NCT03442764Non-obstructive Hypertrophic Cardiomyopathy · United States2CompletedBristol-Myers SquibbJan 7, 202059
NCT02842242Cardiomyopathy, Hypertrophic · United States2CompletedBristol-Myers SquibbNov 201721
NCT02480296Healthy · Australia1CompletedBristol-Myers SquibbJul 201660
NCT02356289Cardiomyopathy, Hypertrophic · United Kingdom1CompletedBristol-Myers SquibbJul 201548
NCT02329184Cardiomyopathy, Hypertrophic · United States1CompletedBristol-Myers SquibbMar 201615

How it is read

Names in the registry

  • “Mavacamten”, 12 entries
  • “mavacamten”, 5 entries
  • “MYK-461”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.